On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Foresight was founded by Stanford University physicians and scientists Maximilian Diehn, M.D., Ph.D., Ash Alizadeh, M.D., Ph.D., and David Kurtz, M.D., Ph.D., together with Jake Chabon, Ph.D., Foresight’s chief scientific officer and chief executive officer. The company has authored more than 40 scientific publications and presentations and partnered with more than 30 biopharma and academic researchers.
The Wilson Sonsini team that advised Foresight on the transaction included:
M&A
Marty Korman
Todd Cleary
Phil McGill
Hallee Moore
Elia Perez Villamarin
Rayna Guo
Matt Fleming
Corporate
Brent Fassett
James Kim
Esther Lim
Technology Transactions
Ian Edvalson
Nguyen Pham
Christina Fuleihan
Patents and Innovations
Maya Skubatch
Rex Watkins
Julia Kennedy-Darling
Business Advisory
Matthew Meyer
Employee Benefits and Compensation
Brandon Gantus
Kristen Stidham
Emma Wilcox
Antitrust and Competition
Jamillia Ferris
Michelle Yost Hale
Kim Biagioli
Corporate Finance
David Hu
Employment Law
Matt Gorman
Chimene Cooper
Data, Privacy, and Cybersecurity
Matt Staples
Michael O'Brien
FDA Regulatory
Eva Yin
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech, GenomeWeb, and Contract Pharma.